medcelerator · clinician one-pager
Once-Daily Pill for Adults with Untreated CLL or SLL
Jaypirca (pirtobrutinib) — once-daily pill for adults with previously untreated CLL or SLL and no known 17p deletion
FDA Approved · United States · October 18, 2026
Condition: CLL/SLL
Who this is for
This is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been treated before and have no known 17p deletion. It explains the US prescribing-information section added in October 2026 for Jaypirca (pirtobrutinib), the once-daily oral path through a cancer doctor, and what BRUIN CLL-313 showed against bendamustine plus rituximab. It is not the later-line use after a covalent BTK inhibitor, not the mantle-cell use, and not the same sentence as the broader EU CLL wording. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/jaypirca-pirtobrutinib-untreated-cll